Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial - Wikidata - awgldk - TriplyDB

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

http://www.wikidata.org/entity/Q29620127

about

Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives Genomic diversity of colorectal cancer: Changing landscape and emerging targets Current targeted therapies in the treatment of advanced colorectal cancer: a review Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy Recent updates of precision therapy for gastric cancer: Towards optimal tailored management Targeting gastrointestinal stromal tumors: the role of regorafenib Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer Molecular testing to optimize therapeutic decision making in advanced colorectal cancer Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases.Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors Pharmacologic resistance in colorectal cancer: a review Novel therapeutic agents in the treatment of metastatic colorectal cancer Molecular approach to genetic and epigenetic pathogenesis of early-onset colorectal cancer Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer Profile of nintedanib in the treatment of solid tumors: the evidence to date Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update Molecular profiling in the treatment of colorectal cancer: focus on regorafenib Biomarkers of Angiogenesis in Colorectal Cancer Treatment of colorectal cancer in the elderly More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses Management of regorafenib-related toxicities: a review Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications Anti-angiogenic agents in metastatic colorectal cancer Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials Management of colorectal cancer Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?Broad targeting of angiogenesis for cancer prevention and therapy Molecular therapy of colorectal cancer: progress and future directions Cancer concepts and principles: primer for the interventional oncologist-part II

P2860

Q26738801-FBE04E47-3741-43CF-AE11-00324086FD75 Q26739052-9CD88211-A5C9-422F-B4F7-CF98FE8DC4A6 Q26740067-7834BD1C-6BF7-4509-AE97-19EEF2940176 Q26745418-D40E99E4-DB6F-4701-931B-101878666831 Q26746246-78E600AB-CDFD-47CB-82F4-C71897C05170 Q26747162-5FA93AEF-8AB4-4748-A17D-5F841613BADB Q26748924-4B245304-E532-472D-8037-D48DB3261A9B Q26749012-E749E89E-75DC-4AE5-9458-69487E16AC71 Q26751344-B73AA3FD-F6AF-4827-9FCE-C88E6101CBD6 Q26752747-947E1E19-215C-4E54-A9C4-648A3DF6F1F7 Q26752752-FA0E24D1-C55D-4CA3-A6F3-A0EA5756DB60 Q26764892-D347E03D-737C-4051-B75E-E583A9936F5E Q26769850-4C0B1BB4-2552-420D-97E1-86BD8B7E36DF Q26769932-85FFEB65-2FEE-4D63-8A2E-3945D4E9B495 Q26769935-BDD92733-01CF-49FB-9721-9C1C69B5ADB1 Q26774605-29F213E6-7E8B-44EB-BD64-8B979F389A66 Q26774713-D5BE026E-1593-4F30-AF1F-522047E9396F Q26775134-A7A15EEC-469B-43ED-B878-C6FB8A5D1F57 Q26775522-D2B7ECA0-1C8D-41BF-8B9E-7A54098AB994 Q26778004-61FB26BB-9AC9-43C2-9EF4-18470DD52B87 Q26778296-B506194F-32E7-496D-8E54-E3A4AAEA2BB8 Q26778891-3AE55331-5728-4A16-AFBE-E2CCFB7C3982 Q26781457-53F7851A-E3B6-42E2-9EE7-89685428D055 Q26781662-34C6B8E7-7D6E-43E3-83BB-D845754E0FFB Q26782585-6571E6A0-78E4-44A1-BAA9-34C60E8D9A61 Q26786243-43224888-776C-43C1-9251-C495515D4AD4 Q26795561-852BD491-633A-4EE8-AFF2-DE8B953B4406 Q26801718-68C918F7-0969-4F19-A246-22539225DB1E Q26801911-D236505E-226B-4934-88C3-F1F2AC6FCBEA Q26821956-184D6467-C48C-403C-9666-6600FC49954B Q26822790-67ED28C4-7517-45D6-B4DF-84F2F06C0CBF Q26823550-6DC727B9-F1F1-4C14-9132-808ED8148AB7 Q26826817-DA739AF9-D933-402C-83A6-A1963176FE87 Q26851417-24E56802-947C-49C4-9E5A-270A85BE89C5 Q26858892-0E815B4F-0733-49C1-B08D-C26BC88EEAC7 Q27002388-62E7DDD6-55D9-43E9-AD17-E8FFB4C33F0B Q27002538-789EE50C-2642-417A-A543-B6D43A18F675 Q27002903-68E36AAC-9350-46EB-ABA0-37CD35F647BB Q27005764-FDE5B1D8-0A7B-41BB-808F-02AA071DF161 Q27010961-C2F638F5-08D5-44C2-B162-B004428023CE

P2860

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

http://www.wikidata.org/entity/Q29620127

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Regorafenib monotherapy for pr ...... cebo-controlled, phase 3 trial

@ast

Regorafenib monotherapy for pr ...... cebo-controlled, phase 3 trial

@en

type

label

Regorafenib monotherapy for pr ...... cebo-controlled, phase 3 trial

@ast

Regorafenib monotherapy for pr ...... cebo-controlled, phase 3 trial

@en

prefLabel

Regorafenib monotherapy for pr ...... cebo-controlled, phase 3 trial

@ast

Regorafenib monotherapy for pr ...... cebo-controlled, phase 3 trial

@en

P1433

Q29620127-ED9ACD7C-52FD-42F8-870E-A07B3DDE9713

P1476

Q29620127-8C288E1D-66B0-413A-A33E-FE0C6ADF8CA3

P2093

Q29620127-00D1CA86-B119-4D83-8B77-6E854FE9AEA9

Q29620127-0F6C08C4-999A-480C-AC23-ED3622D63BCA

Q29620127-18F3C175-D868-4446-9F12-00CE71A6EA8D

Q29620127-1B50A1B6-3EF6-4BCD-8965-C0460EC4CDAD

Q29620127-2CD82537-B894-47E2-AD79-52040A8BD9D1

Q29620127-2DC1224C-5E2A-4C8E-84D3-5BD5EF084221

Q29620127-2EA08152-C10A-4088-B681-29C0655C9E02

Q29620127-4B43228E-13C9-499A-AAD3-DBC4819CBD85

Q29620127-63B4DABD-B622-47D7-8B5A-AF9125C80059

Q29620127-800321B2-A37F-4888-B342-46BBAF2663A3

P304

Q29620127-E3314F4D-06BC-45CA-AC1D-99EE06D8E1F9

P31

Q29620127-34D83379-7C71-4356-8A7C-610D1485D430

P3181

Q29620127-22789020-907F-4B2A-9AA6-E019C9AA3E1F

P356

Q29620127-6149F9FE-DE2A-48C9-8900-01559576C082

P407

Q29620127-977FD1E1-6F77-4B7C-97DC-9D2D8F92C6DE

P433

Q29620127-FC6B8038-EC9B-4166-B75B-E52F3196DD3C

P478

Q29620127-7F36CB40-72BE-4917-88D6-B6C85FC2A6F4

P50

Q29620127-9F43CD21-749F-41A1-869B-9BF5576A48F4

P577

Q29620127-78C9C7DB-DD3A-45CD-874C-3A530B820CC7

P5875

Q29620127-58DC1472-565F-45E0-9FDB-7F879AD00687

P698

Q29620127-25F863FB-CCC5-4A8D-87CD-79C2423C0AB6

P921

Q29620127-39C9A122-E883-4ABE-8C09-572CACC67C34

Q29620127-59394B5E-31A3-4048-BD6F-CF0E325D87FC

Q29620127-8C0B11EA-6ADF-4ED4-8DAD-22B659554716

Q29620127-C75DAD0B-BE00-4D98-AE82-9627235A4C17

P3181

P356

S0140-6736(12)61900-X

P1433

P1476

Regorafenib monotherapy for pr ...... cebo-controlled, phase 3 trial

@en

P2093

Adenis A

http://www.w3.org/2001/XMLSchema#string

Barone C

http://www.w3.org/2001/XMLSchema#string

Bouché O

http://www.w3.org/2001/XMLSchema#string

Cihon F

http://www.w3.org/2001/XMLSchema#string

Cupit L

http://www.w3.org/2001/XMLSchema#string

Falcone A

http://www.w3.org/2001/XMLSchema#string

Goldberg RM

http://www.w3.org/2001/XMLSchema#string

Grothey A

http://www.w3.org/2001/XMLSchema#string

Humblet Y

http://www.w3.org/2001/XMLSchema#string

Laurent D

http://www.w3.org/2001/XMLSchema#string

P304

303-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

32771

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(12)61900-X

http://www.w3.org/2001/XMLSchema#string

P407

P433

9863

http://www.w3.org/2001/XMLSchema#string

P478

381

http://www.w3.org/2001/XMLSchema#string

P50

Josep Tabernero

P577

2013-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233767614

http://www.w3.org/2001/XMLSchema#string

P698

23177514

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

phase III clinical trial

multicenter trial